GFR90 was formed to commercialize and further develop a WEARABLE ARTIFICIAL KIDNEY. This award-winning device has been in development for over eight years, has patents in Canada, USA and other regions, and has been successfully used with dialysis patients. There are over 800,000 dialysis patients in North America. Most of these must attend a dialysis clinic or hospital two to three times a week for dialysis because they suffer from end stage kidney disease, that is, their kidneys no longer work effectively. Although this is life-saving therapy, this intermittency creates medical, social, and mental health issues which result in reduced quality and length of life. Patients feel lethargy, nausea, and fatigue so much so that holding a full time job or attending school is very difficult. The solution is to change dialysis from an intermittent therapy to a continuous therapy - just like healthy kidneys. This will smooth out the fluid accumulation and relieve the work overload it causes on the heart. The intermittency issues with current dialysis are so severe that the FDA and the US White House have issued statements to try to address them by encouraging industry to solve the problem. GFR90 has the solution: a wearable dialysis machine that is lightweight and battery operated so patients wear it during normal activities every day - activities like preparing dinner, gardening, or attending a concert. This near continuous dialysis functions more like healthy kidneys and attenuates the huge swings in body fluids. Scheduled to enter the market in North America within 3 years with their first wearable artificial kidney, GFR90 is further development and commercialization stages of this remarkable device. If you are interested in knowing more, please go to www.GFR90.com. or contact Norm Tiffin at norm.tiffin@gfr90.com.